RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells

Tumor Biology

Volumn 31, Issue 3, 2010, Pages 217-224

  Xu, Qin ^a   Liu, Xiuming ^a   Cai, Yili ^a   Yu, Youcheng ^b   Chen, Wantao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

ADAM9; Adenoid cystic carcinoma; Gene silencing; Metalloproteinase; Metastasis

Indexed keywords

ADAM PROTEIN; ADAM9 PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; ADAM9 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADENOID CYSTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CARCINOMA CELL; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA INTERFERENCE; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ADAM PROTEINS; ANIMALS; CARCINOMA, ADENOID CYSTIC; CELL LINE, TUMOR; FEMALE; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; RNA INTERFERENCE;

EID: 77953277942     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0034-8     Document Type: Article

References (25)

1. Rapidis AD, Givalos N, Gakiopoulou H, Faratzis G, Stavrianos SD, Vilos GA, et al. Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol. 2005;41:328-35.
2. Hu K, Li SL, Gan YH, Wang CY, Yu GY. Epiregulin promotes migration and invasion of salivary adenoid cystic carcinoma cell line SACC-83 through activation of ERK and Akt. Oral Oncol. 2009;45:156-63.
3. Becherer JD, Blobel CP. Biochemical properties and functions of membrane-anchored metallprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol. 2003;54:101-23.
4. Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res. 2009;15:1140-4.
5. Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 2008;90:369-79.
6. Peduto L, Reuter VE, Shaffer DR, Scher HI, Blobel CP. Critical function for ADAM9 in mouse prostate cancer. Cancer Res. 2005;65:9312-9.
7. O'Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer. 2003;105:754-61.
8. Fritzsche FR, Jung M, Tölle A, et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol. 2008;54:1097-106.
9. Huang D, Chen W, Zhang Z, Zhang P, He R, Zhou X, et al. Identification of genes with consistent expression alteration pattern in ACC-2 and ACC-M cells by cDNA array. Chin Med J (Engl). 2003;116:448-52.
10. Ikeda S, Fujimori M, Shibata S, et al. Combined immunohistochemistry of β-catenin, cytokeratin 7, and cytokeratin 20 is usefulin discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer. 2006;2:31.
11. Xu Q, Zhang Z, Zhang P, Chen W. Antisense oligonucleotides and all-trans retinoic acid have a synergistic anti-tumor effect on oral squamous cell carcinoma. BMC Cancer. 2008;8:159.
12. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550-3.
13. Cuneo KC, Fu A, Osusky KL, Geng L. Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis. Anticancer Drugs. 2007;18:349-55.
14. Chen J, Peng H, Ou-Yang X, He X. Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells. Melanoma Res. 2008;18:322-9.
15. Nakashima Y, Yano M, Kobayashi Y, Moriyama S, Sasaki H, Toyama T, et al. Endostatin gene therapy on murine lung metastases model utilizing cationic vector-mediated intravenous gene delivery. Gene Ther. 2003;10:123-30.
16. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Röcken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol. 2005;26:17-24.
17. Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Röcken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. Cancer Res Clin Oncol. 2005;131:41-8.
18. Zheng X, Jiang F, Katakowski M, et al. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci. 2007;98:674-84.
19. Rocks N, Estrella C, Paulissen G, et al. The metalloproteinase ADAM-12 regulates bronchial epithelial cell proliferation and apoptosis. Cell Prolif. 2008;41:988-1001.
20. Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW, Liu TY. Increase of disintergin metalloprotease 10(ADAM10) expression in oral squamous cell carcinoma. Cancer Lett. 2007;245:33-43.
21. Fritzsche FR, Wassermann K, Jung M, Tölle A, Kristiansen I, Lein M, et al. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer. 2008;8:179-87.
22. Boelens MC, Kok K, Van der Vlies P, et al. Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer. 2009;66:372-8.
23. Zigrino P, Mauch C, Fox JW, Nischt R. Adam-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer. 2005;116:853-9.
24. Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M, et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 2005;65:4728-38.
25. Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 2004;64:4190-6.